From Peter J. Gordon’s Hole Ousia website:
“I noticed this ‘Special Article’ published in the October 2015 edition of the British Journal of Psychiatry. It details a novel antipsychotic medication called Lurasidone (trade name Latuda). … I would anticipate that this is the start of a programme to educate psychiatrists in the UK on this new drug.”
Note that Latuda is approved for the treatment of ‘schizophrenia’ in a number of countries including the UK, and also approved in the USA and Canada for the treatment of major depressive episodes associated with ‘bipolar 1 disorder’.
Also note that:
- One of the two co-authors of the Special Article – under “declaration of interest” – lists no fewer than twenty five pharmaceutical companies from which they have received money, research money or “honoraria” in the previous 12 months alone.
- The other co-author has received 704 payments totalling $655,200 from drug or medical device companies, including $181,000 from the manufacturer of Latuda.
Find out more here.
Find out which psychiatrists (in the USA) have received which amounts of money – from August 2013 to December 2015 – using a searchable database called Docs for Dollars.